Plasma Exchange in Clinical Practice

Filipov, Jean; Zlatkov, Б.; Dimitrov, Emil

doi:10.5772/intechopen.76094

Cited by 5 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This translates to greater removal of immune complexes but with debatable effects on immunomodulation in sepsis. 6,45 Head-to-head trials comparing membrane and centrifugal TPE procedures in patients with severe sepsis have not been performed; studies involving patients without sepsis but required TPE reported equivocal results between these 2 modes. 46,47 Our review suggests no significant difference in outcome between centrifugal and membrane TPE.…”

Section: Discussionmentioning

confidence: 99%

Survival Benefits of Therapeutic Plasma Exchange in Severe Sepsis and Septic Shock: A Systematic Review and Meta-analysis

Lee

Kanesan²,

Leow

et al. 2023

J Intensive Care Med

View full text Add to dashboard Cite

Objectives To summarize the role of therapeutic plasma exchange (TPE) in critically ill adults and children with severe sepsis. Data collection A systematic search was performed using the following databases: Medline, EMBASE, CINAHL, and Cochrane from January 1990 till December 2022. Comparative studies of TPE in severe sepsis were selected. Adult and pediatric data were analyzed separately. Data synthesis Eight randomized control trials and 6 observational studies (n = 50,142 patients) were included. Centrifugal TPE was the most common modality (209/280, 74.6% adults and 952/1026, 92.7% children). Every TPE study utilized different volume exchanges. Most TPE sessions (1173/1306, 89.8%) employed fresh frozen plasma (FFP) as replacement fluid and heparin as anticoagulant. Adults with severe sepsis supported with TPE using FFP had lower mortality (risk ratio, RR: 0.64 [95% confidence interval, CI: 0.49, 0.84]) compared to those who did not. In contrast, TPE was associated with increased mortality in septic children without thrombocytopenia-associated multiorgan failure ( RR: 2.23, 95% CI: 1.93, 2.57). There was no difference in outcomes in patients supported with centrifugal and membrane TPE. In both populations, patients supported on TPE as a continuous regime had poorer outcome. Conclusion Current evidence indicates that TPE is a potential adjunct therapy in adults with severe sepsis but not in children.

show abstract

Section: Discussionmentioning

confidence: 99%

Survival Benefits of Therapeutic Plasma Exchange in Severe Sepsis and Septic Shock: A Systematic Review and Meta-analysis

Lee

Kanesan²,

Leow

et al. 2023

J Intensive Care Med

View full text Add to dashboard Cite

show abstract

Plasmapheresis

Azeem

Emanuel

Malhotra

2022

Procedures and Protocols in the Neurocritical Care Unit

View full text Add to dashboard Cite

Pure Biologics – From a Bootstrapped Boutique CRO to an Integrated Drug Discovery Public Company

Deshmukh

Jurek

Jeleń

et al. 2020

TTE

View full text Add to dashboard Cite

The present article is a case study of a Polish biopharmaceutical company, “Pure Biologics”. The company was founded in 2010 by a group of scientists and, over the last nine years, grew substantially from just a few individuals to nearly one hundred professionals. Initially, a privately-funded civil partnership, Pure Biologics, has been transformed into a publicly-traded company. Such a transformation has been possible not only because of the expertise and growing experience of corporate management, but also the specific economic environment and substantial public funding dedicated to innovative Small and Medium Enterprises (SMEs).

show abstract

Plasma Exchange in Clinical Practice

Cited by 5 publications

References 25 publications

Survival Benefits of Therapeutic Plasma Exchange in Severe Sepsis and Septic Shock: A Systematic Review and Meta-analysis

Survival Benefits of Therapeutic Plasma Exchange in Severe Sepsis and Septic Shock: A Systematic Review and Meta-analysis

Plasmapheresis

Pure Biologics – From a Bootstrapped Boutique CRO to an Integrated Drug Discovery Public Company

Contact Info

Product

Resources

About